Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3
US9931341B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9931341-B2 |
| Application number | US-201514844041-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 3, 2015 |
| Priority date | Dec 12, 2011 |
| Publication date | Apr 3, 2018 |
| Grant date | Apr 3, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a FGFR3-related skeletal disease which comprises the step of administering a therapeutically effective amount of at least one antagonist of the FGFR3 tyrosine kinase receptor of formula: or a composition comprising such an antagonist, to a subject in need thereof, and treating the FGFR3-related skeletal disease in said subject, wherein the FGFR3-related skeletal disease is achondroplasia.
Assignees
Inventors
Classifications
Operations & Transport · mapped topic
grafted on to rubbers · CPC title
used for thermoforming · CPC title
containing four or more polymers in a blend · CPC title
Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as reinforcement · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9931341B2 cover?
- The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med, Univ Paris Descartes, Centre Nat Rech Scient, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/506. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).